CPSE:VELO

Stock Analysis Report

Executive Summary

Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation.

Snowflake

Fundamentals

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Veloxis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.1%

VELO

-0.3%

DK Pharmaceuticals

0.3%

DK Market


1 Year Return

175.8%

VELO

9.7%

DK Pharmaceuticals

16.3%

DK Market

Return vs Industry: VELO exceeded the Danish Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: VELO exceeded the Danish Market which returned 16.3% over the past year.


Shareholder returns

VELOIndustryMarket
7 Day5.1%-0.3%0.3%
30 Day-1.4%-0.8%-0.6%
90 Day20.3%4.1%1.3%
1 Year175.8%175.8%16.0%9.7%19.8%16.3%
3 Year201.2%201.2%32.6%17.7%37.1%25.7%
5 Year87.9%87.9%32.5%10.5%73.4%48.6%

Price Volatility Vs. Market

How volatile is Veloxis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Veloxis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VELO (DKK3.8) is trading below our estimate of fair value (DKK8.43)

Significantly Below Fair Value: VELO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VELO is poor value based on its PE Ratio (370x) compared to the Pharmaceuticals industry average (23x).

PE vs Market: VELO is poor value based on its PE Ratio (370x) compared to the Danish market (14.5x).


Price to Earnings Growth Ratio

PEG Ratio: VELO is poor value based on its PEG Ratio (4.7x)


Price to Book Ratio

PB vs Industry: VELO is overvalued based on its PB Ratio (91.5x) compared to the XE Pharmaceuticals industry average (3.2x).


Next Steps

Future Growth

How is Veloxis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

79.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VELO's forecast earnings growth (79.5% per year) is above the savings rate (0.2%).

Earnings vs Market: VELO's earnings (79.5% per year) are forecast to grow faster than the Danish market (11.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VELO's revenue (32.9% per year) is forecast to grow faster than the Danish market (6.7% per year).

High Growth Revenue: VELO's revenue (32.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VELO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Veloxis Pharmaceuticals performed over the past 5 years?

24.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VELO has become profitable over the past 5 years, growing earnings by 24.6% per year.

Accelerating Growth: VELO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: VELO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: Whilst VELO's Return on Equity (24.58%) is high, this metric is skewed due to their high level of debt.


Return on Assets

ROA vs Industry: VELO has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: VELO's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Veloxis Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: VELO's short term assets ($55.1M) exceeds its short term liabilities ($16.3M)

Long Term Liabilities: VELO's short term assets (55.1M) do not cover its long term liabilities (60.5M)


Debt to Equity History and Analysis

Debt Level: VELO's debt to equity ratio (562.3%) is considered high

Reducing Debt: Insufficient data to determine if VELO's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: VELO's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: VELO's interest payments on its debt are not well covered by EBIT (0.3x coverage).


Balance Sheet

Inventory Level: VELO has a low level of unsold assets or inventory.

Debt Coverage by Assets: VELO's debt is not covered by short term assets (assets are 0.9x debt).


Next Steps

Dividend

What is Veloxis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.7%markettop25%5.2%industryaverage3.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VELO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VELO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VELO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VELO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VELO's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

What is the CEO of Veloxis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Craig Collard (53yo)

3.8yrs

Tenure

0

Mr. Craig Alexander Collard is an Independent Director at TerrAscend Corp. since December 6, 2018. He has been Independent Director of Opiant Pharmaceuticals, Inc. since October 29, 2018. He has been the C ...


Management Age and Tenure

1.1yrs

Average Tenure

Experienced Management: VELO's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Age and Tenure

12.3yrs

Average Tenure

55yo

Average Age

Experienced Board: VELO's board of directors are seasoned and experienced ( 12.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Craig Collard (53yo)

    President & CEO

    • Tenure: 3.8yrs
  • Ira Duarte

    Chief Financial Officer

    • Tenure: 1.1yrs
  • Mark Hensley

    Chief Commercial Officer

    • Tenure: 0.8yrs

Board Members

  • Paul Wotton (59yo)

    Independent Director

    • Tenure: 3.3yrs
  • Mette Agger (55yo)

    Deputy Chairman

    • Tenure: 3.5yrs
  • Mike Heffernan (55yo)

    Independent Chairman of the Board

    • Tenure: 3.5yrs
  • Anders Götzsche (52yo)

    Independent Director

    • Tenure: 11.5yrs
  • Marc Pescovitz

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs
  • John Lake

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs
  • Josep M. Grinyó

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Robert Gaston

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Klemens Budde

    Member of Scientific Advisory Board

    • Tenure: 12.3yrs
  • Rita Alloway

    Member of Transplant Scientific Advisory Board

    • Tenure: 12.3yrs

Company Information

Veloxis Pharmaceuticals A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Veloxis Pharmaceuticals A/S
  • Ticker: VELO
  • Exchange: CPSE
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ø6.597b
  • Shares outstanding: 1.74b
  • Website: https://www.veloxis.com

Number of Employees


Location

  • Veloxis Pharmaceuticals A/S
  • Amerika Plads 37
  • Copenhagen
  • Capital Region of Denmark
  • 2100
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VELOCPSE (OMX Nordic Exchange Copenhagen)YesOrdinary SharesDKDKKNov 2006
L8HDB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2006
0IVILSE (London Stock Exchange)YesOrdinary SharesGBDKKNov 2006
LFCY.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2006
VELOcBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBDKKNov 2006

Biography

Veloxis Pharmaceuticals A/S, a specialty pharmaceutical company, engages in enhancing the lives of transplant patients by identifying, developing, and commercializing products in transplantation. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 20:51
End of Day Share Price2019/10/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.